safety profile – Page 29 – Communicable Diseases Research

Assessment of Chloroquine and Hydroxychloroquine Safety Profiles: A Systematic Review and Meta-Analysis

Pharmacology

Published on 2020-10-142022-10-31
Journal: Frontiers in Pharmacology [Category] COVID-19,

Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines

Immunology

Published on 2020-10-022022-11-01
Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS,

[키워드] adverse effects adverse events of special interest (AESI) antibody antibody dependent enhancement (ADE) approach approaches Bacillus Calmette-Guérin (BCG) candidate candidate vaccine Cell mediated immunity clinical trial Coalition for Epidemic Preparedness Innovations (CEPI) COVID-19 Critical effective Efficacy effort Ensuring globe groups Human immune immune response immunize immunogenic impacts in healthy individual Innate immunity knowledge likelihood Neutralizing antibodies occur pandemic Progress PROTECT quest required Safe safety profile SARS-CoV-2 SARS-CoV-2 vaccine shown Spike protein stimulate Surveillance T cell response Trial Vaccine Vaccine development virus
[DOI] 10.3389/fimmu.2020.579250 PMC 바로가기 [Article Type] Immunology

Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?

호흡기 플루오로퀴놀론, 레보플록사신 및 목시플록사신이 COVID-19의 보조 치료제로 유용할 수 있습니까?

Article

Published on 2020-10-012022-09-11
Journal: Archives of medical research [Category] SARS, 신약개발, 치료제,

[키워드] adjunct adjuncts anti-inflammatory drug Anti-inflammatory drugs Antibiotics antimicrobial agents antiretroviral drug Antiviral antiviral action antiviral activity attenuation binding broad spectrum characterized Chloroquine ciprofloxacin CMV community-acquired pneumonia comparable Concentration COVID-19 COVID-19 pandemic Cytokines derivative effective therapy exhibiting Fluoroquinolone HCV HIV HSV-1 immunomodulatory immunomodulatory properties in silico Infection Inflammatory response inhibit SARS-CoV-2 levofloxacin Lungs management moxifloxacin nelfinavir papovavirus pharmacokinetic Pneumonia pro-inflammatory cytokines prodrome protease Protease inhibitor quinoline Replication researcher respiratory respiratory infections safety profile SARS-CoV-2 SARS-CoV-2 replication shown therapeutic agent therapeutic agents treat Treatment vaccinia virus
[DOI] 10.1016/j.arcmed.2020.06.004 PMC 바로가기 [Article Type] Article

Repurposing existing drugs for COVID-19: an endocrinology perspective

Correspondence

Published on 2020-09-292022-10-28
Journal: BMC Endocrine Disorders [Category] COVID-19, SARS,

[키워드] absence ACE inhibitor ACE2 affected Ageusia aging androgen angiotensin receptor blocker angiotensin-converting enzyme-2 Anosmia Anti-androgen ARB arthralgia assessment candidate caused Clinical effect clinical testing clinical trial coronavirus 2 correlated COVID-19 COVID-19 patient death description Dexamethasone diabetes drug drug treatment effective therapy Efficacy elicited Endocrine Evidence familiarity fatigue Fever Glucocorticoids heterogeneous Hospitalization hypertension include Infection inherent inhibitor lack less mechanical ventilation methodological Mild-to-moderate myalgia N-acetyl cysteine NAC obesity Other outcome pandemic patients Perspective public health systems RAAS reduce mortality reduction in repurposing Research researcher respiratory risk Safe safety profile SARS-CoV-2 severe COVID-19 severely ill patient Symptom target therapeutic options TMPRSS2 transmembrane serine protease while with COVID-19 worse prognosis
[DOI] 10.1186/s12902-020-00626-0 PMC 바로가기 [Article Type] Correspondence

Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review

Review

Published on 2020-09-112022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] animal models Anti-inflammatory benefit building Cancer Cancer therapy cardiac cardio-oncology clinical outcomes clinical trial coronavirus 2019 (COVID-19) coronavirus disease COVID-19 COVID-19 infection COVID-19 therapy Cytokine release syndrome decrease drug Efficacy effort Evidence Human hyper-inflammatory phase identify Immunomodulatory therapies Immunotherapy Inflammation Intervention low dose dexamethasone mechanism Microvascular thrombosis outcomes pandemic physician potential therapy proliferation recovery Repurposed drug repurposing review safety profile screened therapeutic therapy Trial vascular permeability Volume
[DOI] 10.3390/jcm9092935 PMC 바로가기 [Article Type] Review

Ramatroban as a Novel Immunotherapy for COVID-19

Article

Published on 2020-08-292022-10-31
Journal: Journal of molecular and genetic medicine : an international journal of biomedical research [Category] COVID-19,

Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed

Review

Published on 2020-08-242022-10-30
Journal: Nutrients [Category] COVID-19, MERS,

[키워드] acute lung injury acute respiratory syndrome adverse effect Anti-inflammatory anti-oxidative Anxiety ARDS Care caused clinical Clinical features Clinical outcome clinical trial clinical trials contribute coronavirus Coronaviruses COVID-19 COVID-19 pandemic critical care patient Cytokine storm death disease distress effective Evidence exaggerated immune response excessive inflammation Health homogenous humans immune response imperative individual Inflammation melatonin pandemic of COVID-19 Pathogenesis pathology patients professional progression reducing reported respiratory disorder safety profile SARS-CoV-2 Sedation subsequent syndrome Treatment triggering vascular permeability
[DOI] 10.3390/nu12092561 PMC 바로가기 [Article Type] Review

Novel Use of Vitamin B2 as a Fluorescent Tracer in Aerosol and Droplet Contamination Models in Otolaryngology

Original Articles

Published on 2020-08-142022-10-27
Journal: The Annals of Otology, Rhinology, and Laryngology [Category] Coronavirus, MERS, SARS,

Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial

중증 또는 치명적인 COVID-19 폐렴의 치료를 위한 Auxora 대 표준 치료: 무작위 대조 시험의 결과

Research

Published on 2020-08-142022-08-13
Journal: Critical Care [Category] MERS, 임상,

[키워드] 95% CI Abstract Administered adverse event Auxora baseline blinded calcium Calcium release-activated calcium Calcium release-activated calcium channel inhibitors channel inhibitor conducted COVID-19 COVID-19 pneumonia CRAC CRAC channel inhibitor CRAC channel inhibitors Critical cytokine demonstrated died dose Efficacy Enrollment FDA Fewer patient Fewer patients Guidance intravenously Invasive mechanical ventilation mechanical ventilation median time nine novel Open-label open-label study design Ordinal Scale outcome PaO Patient patient population patients with COVID-19 placebo-controlled study Pneumonia Proinflammatory cytokine Proinflammatory response proportion Pulmonary endothelium randomization Randomized Randomized controlled trial rate ratio receive receiving Regulatory respiratory respiratory complication Respiratory complications Result resulting risk safety profile Serious Adverse Event Serious Adverse Events Severe COVID-19 pneumonia significantly Standard of care study enrollment the median Time to recovery Tolerability transition Treatment Trial registration Two patient two patients
[DOI] 10.1186/s13054-020-03220-x PMC 바로가기 [Article Type] Research

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment

Review article

Published on 2020-08-012022-10-05
Journal: Journal of the American Academy of Dermatology [Category] SARS, 치료법,